Other Events ·
Conexeu Sciences Inc. announced the completion of the P.R.O.O.F. phase of its CXU™ platform preclinical program…
CNXUConexeu Sciences Inc.
Conexeu Sciences Inc. announced the completion of the P.R.O.O.F. phase of its CXU™ platform preclinical program, demonstrating successful tissue restoration in both small-volume facial and large-volume subcutaneous models. The 12-month study met performance benchmarks for injectability and volumizing performance, supporting the company's planned 510(k) regulatory submission for wound care in Q1 2027. Conexeu Sciences Inc. is a biotechnology company developing a flowable collagen platform for medical aesthetics and wound care applications.